HRP20100240T1 - Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus - Google Patents
Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus Download PDFInfo
- Publication number
- HRP20100240T1 HRP20100240T1 HR20100240T HRP20100240T HRP20100240T1 HR P20100240 T1 HRP20100240 T1 HR P20100240T1 HR 20100240 T HR20100240 T HR 20100240T HR P20100240 T HRP20100240 T HR P20100240T HR P20100240 T1 HRP20100240 T1 HR P20100240T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- polypeptide
- sequence
- amino acid
- immunogen
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 37
- 229920001184 polypeptide Polymers 0.000 title claims abstract 36
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 36
- 230000001681 protective effect Effects 0.000 title claims abstract 6
- 230000028993 immune response Effects 0.000 title claims abstract 4
- 230000001939 inductive effect Effects 0.000 title claims 2
- 241000191967 Staphylococcus aureus Species 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 14
- 230000002163 immunogen Effects 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000036039 immunity Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 210000002421 cell wall Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Polipeptidni imunogen, naznačen time što sadrži aminokiselinsku sekvencu koja je najmanje 90% identična sekvenci SEQ ID NO: 1, pri čemu navedeni polipeptid osigurava zaštitni imunitet protiv S. aureus i pri čemu, ako je prisutno jedna ili više dodatnih polipeptidnih regija, tada navedene dodatne regije ne osiguravaju karboksil terminus koji sadrži aminokiseline 609-645 sekvence SEQ ID NO: 2. Patent sadrži još 30 patentnih zahtjeva.
Claims (31)
1. Polipeptidni imunogen, naznačen time što sadrži aminokiselinsku sekvencu koja je najmanje 90% identična sekvenci SEQ ID NO: 1, pri čemu navedeni polipeptid osigurava zaštitni imunitet protiv S. aureus i pri čemu, ako je prisutno jedna ili više dodatnih polipeptidnih regija, tada navedene dodatne regije ne osiguravaju karboksil terminus koji sadrži aminokiseline 609-645 sekvence SEQ ID NO: 2.
2. Polipeptid prema patentnom zahtjevu 1, naznačen time što se navedeni polipeptid sastoji od aminokiselinske sekvence koja je najmanje 90% identična sekvenci SEQ ID NO: 3 ili njenog fragmenta koji sadrži aminokielinsku sekvencu koja je najmanje 90% identična sekvenci SEQ ID NO: 1.
3. Polipeptid prema patentnom zahtjevu 2, naznačen time što se navedeni polipeptid sastoji od aminokiselinske sekvence koja je najmanje 94% identična sekvenci SEQ ID NO: 3, ili njenog fragmenta koji sadrži aminokiselinsku sekvencu koja je najmanje 94% identična sekvenci SEQ ID NO: 1.
4. Polipeptid prema patentnom zahtjevu 3, naznačen time što se navedeni polipeptid sastoji od aminokiselinske sekvence koja je najmanje 94% identična sekvenci SEQ ID NO: 1, SEQ ID NO: 3 ili SEQ ID NO: 42.
5. Polipeptid prema patentnom zahtjevu 1, naznačen time što je navedeni polipeptid - SEQ ID NO: 1, SEQ ID NO: 3 ili SEQ ID NO: 42; ili se razlikuje od navedenih sekvenci prema maksimalno 25 aminokiselinskih zamjena.
6. Polipeptid prema patentnom zahtjevu 5, naznačen time što je navedeni polipeptid SEQ ID NO: 1, SEQ ID NO: 3 ili SEQ ID NO: 42, ili se razlikuje od navedenih sekvenci prema maksimalno 10 aminokiselinskih zamjena.
7. Polipeptid prema patentnom zahtjevu 6, naznačen time što je navedeni polipeptid SEQ ID NO: 1, SEQ ID NO: 3 ili SEQ ID NO: 42, ili se razlikuje od navedenih sekvenci prema maksimalno 5 aminokiselinskih zamjena.
8. Polipeptid prema patentnom zahtjevu 1 naznačen time što je navedeni polipeptid SEQ ID NO: 1, SEQ ID NO: 3 ili SEQ ID NO: 42.
9. Polipeptid prema patentnom zahtjevu 1 naznačen time što se navedeni polipeptid sastoji od aminokiselinske sekvence od SEQ ID NO 1, 3, 7, 17, 20 ili 42 i do 20 dodatnih aminokiselina.
10. Polipeptid prema patentnom zahtjevu 5, naznačen time što se navedeni polipeptid sastoji od aminokiselinske sekvence SEQ ID NO 7, 17 ili 20.
11. Polipeptid prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što mu nedostaju svi, ili većina, drugih polipeptida sa kojim je ovaj polipeptid prirodno povezan.
12. Imunogen, naznačen time što se sastoji od polipeptida prema bilo kojem prethodnom patentnom zahtjevu, pri čemu se navedeni imunogen sastoji od navedene aminokiselinske sekvence i jedne ili više dodatnih regija ili grupa kovalentno vezanih za navedenu sekvencu na karboksil terminusu ili amino terminusu, pri čemu je svaka regija ili grupa nezavisno izabrana od regija ili grupe koji imaju najmanje jedno od slijedećih svojstava: pojačavaju imunitetni odgovor, olakšavaju pročišćavanje ili omogućavaju stabilnost polipeptida.
13. Kompozicija koja je sposobna da inducira zaštitni imunitetni odgovor kod pacijenta, naznačena time što sadrži imunitetno efikasnu količinu imunogena prema bilo kojem od patentnih zahtjeva 1-12 i farmaceutski prihvatljiv nosač.
14. Kompozicija prema patentnom zahtjevu 13, naznačena time što navedena kompozicija dalje sadrži adjuvant.
15. Nukleinska kiselina, naznačena time što sadrži rekombinantni gen koji sadrži nukleotidnu sekvencu koja kodira polipeptidni imunogen prema bilo kojem od patentnih zahtjeva 1-10.
16. Nukleinska kiselina prema patentnom zahtjevu 15, naznačena time što rekombinantni gen ne kodira sekvencu staničnog signalnog peptida i ne kodira signalnu sekvencu za sortiranje staničnog zida.
17. Nukleinska kiselina prema patentnom zahtjevu 16, naznačena time što navedeni rekombinantni gen sadrži jedan ili više kodona optimiziranih za ekspresiju kvasca.
18. Nukleinska kiselina prema patentnom zahtjevu 17, naznačena time što je navedena nukleotidna sekvenca najmanje 50% kodon-optimizirana za ekspresiju u kvascu.
19. Nukleinska kiselina prema patentnom zahtjevu 16, naznačena time što je navedena nukleotidna sekvenca izabrana iz grupe koju čine: SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52 i SEQ ID NO: 53.
20. Nukleinska kiselina prema patentnom zahtjevu 15 ili 19, naznačena time što je navedena nukleinska kiselina - ekspresioni vektor.
21. Rekombinantna stanica, naznačena time što sadrži nukleinsku kiselinu prema bilo kojem od patentnih zahtjeva 15-20.
22. Postupak za pripremu S. aureus polipeptida koji osigurava zaštitni imunitet, naznačen time što sadrži slijedeće korake:
(a) rast rekombinantne stanice prema patentnom zahtjevu 21 pod uvjetima u kojima je polipeptid prema bilo kojem od patentnih zahtjeva 1 do 11 eksprimiran; i
(b) pročišćavanje navedenog peptida.
23. Postupak prema patentnom zahtjevu 22, naznačena time što je navedena rekombinantna stanica S. cerevisiae.
24. Imunogen prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time što je namijenjen za primjenu u postupku liječenja ljudskog tijela putem terapije.
25. Imunogen prema patentnom zahtjevu 24, naznačen time što je namijenjen za osiguravanje zaštitnog imuniteta protiv S. aureus.
26. Imunogen prema patentnom zahtjevu 25, naznačen time što je navedeni pacijent čovjek.
27. Imunogen prema patentnom zahtjevu 25, naznačen time što se navedeni pacijent tretira profilaktički protiv S. aureus infekcije.
28. Imunogen prema patentnom zahtjevu 24, naznačen time što je namijenjen za indukciju anamnestičkog odgovora.
29. Imunogen prema patentnom zahtjevu 28, naznačen time što navedeni anamnestički odgovor ima za rezultat najmanje 3-struko povećanje u geometrijskom titru u odnosu na prethodni titar u roku od 3 dana.
30. Primjena imunogena prema bilo kojem od patentnih zahtjeva 1 do 12, naznačena time što je namijenjena za proizvodnju lijeka za primjenu u postupku kao što je definirano u bilo kojem od patentnih zahtjeva 25 do 29.
31. Imunogen prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time što je u kombinaciji sa dodatnim imunogenima koji su izabrani iz grupe koju čine: jedan ili više dodatnih imunogena S. aureus; jedan ili više imunogena koji ciljano djeluju na jedan ili više drugih organizama Staphylococcus; i jedan ili više imunogena koji ciljano djeluju na druge infektivne organizme.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48984003P | 2003-07-24 | 2003-07-24 | |
| US52011503P | 2003-11-14 | 2003-11-14 | |
| PCT/US2004/023523 WO2005009379A2 (en) | 2003-07-24 | 2004-07-22 | Polypeptides for inducing a protective immune response against staphylococcus aureus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100240T1 true HRP20100240T1 (hr) | 2010-09-30 |
Family
ID=34107815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100240T HRP20100240T1 (hr) | 2003-07-24 | 2010-04-26 | Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20060177462A1 (hr) |
| EP (1) | EP1651166B8 (hr) |
| JP (1) | JP2007502101A (hr) |
| KR (1) | KR20060065643A (hr) |
| AT (1) | ATE457737T1 (hr) |
| AU (1) | AU2004258979B2 (hr) |
| BR (1) | BRPI0412799A (hr) |
| CA (1) | CA2532370A1 (hr) |
| CY (1) | CY1110028T1 (hr) |
| DE (1) | DE602004025579D1 (hr) |
| DK (1) | DK1651166T3 (hr) |
| ES (1) | ES2342778T3 (hr) |
| HR (1) | HRP20100240T1 (hr) |
| IL (1) | IL173253A0 (hr) |
| IS (1) | IS8213A (hr) |
| MX (1) | MXPA06000854A (hr) |
| NO (1) | NO20060898L (hr) |
| NZ (2) | NZ544542A (hr) |
| PL (1) | PL1651166T3 (hr) |
| PT (1) | PT1651166E (hr) |
| RU (1) | RU2337108C2 (hr) |
| SI (1) | SI1651166T1 (hr) |
| WO (1) | WO2005009379A2 (hr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| EP1725575B1 (en) * | 2004-02-18 | 2012-11-28 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against staphylococcus aureus |
| KR20070085457A (ko) * | 2004-10-25 | 2007-08-27 | 더 유니버시티 오브 웨스턴 온타리오 | 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 ＩｓｄＡ, ＩｓｄＢ, 및 ＩｓｄＣ 기재 백신,조성물 및 방법 |
| GB0526038D0 (en) * | 2005-12-21 | 2006-02-01 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| AU2007210170A1 (en) * | 2006-01-27 | 2007-08-09 | Merck Sharp & Dohme Corp. | Antigen-binding proteins targeting S. aureus ORF0657n |
| CA2675992A1 (en) | 2007-01-24 | 2008-11-20 | Merck & Co., Inc. | Polypeptides for inducing a protective immune response against staphylococcus epidermidis |
| EP1987836B1 (en) * | 2007-05-04 | 2011-12-21 | Martin Krönke | Protective staphylococcus aureus vaccine based on cell wall-associated proteins |
| CN101679516B (zh) * | 2007-05-31 | 2013-11-13 | 默沙东公司 | 靶向金黄色葡萄球菌ORF0657n的抗原结合蛋白 |
| EP2185195A2 (en) | 2007-08-16 | 2010-05-19 | Tripep Ab | Immunogen platform |
| US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
| WO2009029831A1 (en) | 2007-08-31 | 2009-03-05 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
| WO2010014304A1 (en) | 2008-07-29 | 2010-02-04 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
| JP2012509665A (ja) | 2008-11-26 | 2012-04-26 | メルク・シャープ・エンド・ドーム・コーポレイション | スタフィロコッカス・アウレウス（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対する防御免疫応答を誘導するポリペプチド |
| KR101773368B1 (ko) | 2009-04-03 | 2017-08-31 | 유니버시티 오브 시카고 | 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법 |
| SG175092A1 (en) | 2009-04-14 | 2011-11-28 | Novartis Ag | Compositions for immunising against staphylococcus aerus |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| JP2013506651A (ja) | 2009-09-30 | 2013-02-28 | ノバルティス アーゲー | Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体 |
| PT2493498T (pt) | 2009-10-30 | 2017-05-24 | Glaxosmithkline Biologicals Sa | Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8 |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| EP2544709A4 (en) * | 2010-03-12 | 2014-01-08 | Univ Pennsylvania | METHODS FOR PREVENTING AND TREATING COLONIZATION, STAPHYLOCOCCUS AUREUS-INDUCED INFECTION AND DISEASE |
| CN103037885B (zh) | 2010-07-02 | 2015-08-26 | 芝加哥大学 | 与蛋白A(SpA)变体相关的组合物和方法 |
| EP2593133A4 (en) | 2010-07-13 | 2014-11-26 | Merck Sharp & Dohme | STAPHYLOCOCCUS AUREUS SURFACE PROTEIN SA1789 AND PROTECTIVE VACCINE BASED ON IT |
| WO2012065034A1 (en) | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Enolase peptide conjugate vaccines against staphylococcus aureus |
| US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
| IN2014CN02152A (hr) | 2011-09-01 | 2015-09-04 | Novartis Ag | |
| WO2013066731A2 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Protective vaccine based on staphylococcus aureus sa2451 protein |
| WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| RU2639287C2 (ru) | 2012-06-27 | 2017-12-20 | Ф. Хоффманн-Ля Рош Аг | Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения |
| US9376487B2 (en) | 2012-07-10 | 2016-06-28 | Merck Sharp & Dohme Corp. | Protective vaccine based on Staphylococcus aureus SA2493 protein |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| GB0014907D0 (en) * | 2000-06-20 | 2000-08-09 | Univ Sheffield | Antigenic polypeptides |
| AT410798B (de) * | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| EP2320233A1 (en) * | 2001-06-15 | 2011-05-11 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| ES2322338T3 (es) * | 2001-11-12 | 2009-06-19 | Novo Nordisk A/S | Purificacion de peptidos por medio de cromatografia de afinidad con iones metalicos. |
| US20080050361A1 (en) * | 2004-10-25 | 2008-02-28 | Heinrichs David E | Staphylococcus aureas specific anti-infectives |
| CA2637598A1 (en) * | 2006-01-18 | 2007-02-14 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
-
2004
- 2004-07-22 CA CA002532370A patent/CA2532370A1/en not_active Abandoned
- 2004-07-22 NZ NZ544542A patent/NZ544542A/en not_active IP Right Cessation
- 2004-07-22 WO PCT/US2004/023523 patent/WO2005009379A2/en active Application Filing
- 2004-07-22 BR BRPI0412799-4A patent/BRPI0412799A/pt not_active Application Discontinuation
- 2004-07-22 JP JP2006521226A patent/JP2007502101A/ja active Pending
- 2004-07-22 US US10/564,458 patent/US20060177462A1/en not_active Abandoned
- 2004-07-22 DK DK04778847.6T patent/DK1651166T3/da active
- 2004-07-22 KR KR1020067001610A patent/KR20060065643A/ko not_active Application Discontinuation
- 2004-07-22 AU AU2004258979A patent/AU2004258979B2/en not_active Ceased
- 2004-07-22 RU RU2006105498/13A patent/RU2337108C2/ru not_active IP Right Cessation
- 2004-07-22 MX MXPA06000854A patent/MXPA06000854A/es active IP Right Grant
- 2004-07-22 DE DE602004025579T patent/DE602004025579D1/de not_active Expired - Lifetime
- 2004-07-22 NZ NZ570750A patent/NZ570750A/en not_active IP Right Cessation
- 2004-07-22 EP EP04778847A patent/EP1651166B8/en not_active Expired - Lifetime
- 2004-07-22 AT AT04778847T patent/ATE457737T1/de active
- 2004-07-22 ES ES04778847T patent/ES2342778T3/es not_active Expired - Lifetime
- 2004-07-22 PL PL04778847T patent/PL1651166T3/pl unknown
- 2004-07-22 PT PT04778847T patent/PT1651166E/pt unknown
- 2004-07-22 SI SI200431389T patent/SI1651166T1/sl unknown
-
2005
- 2005-12-30 IS IS8213A patent/IS8213A/is unknown
-
2006
- 2006-01-19 IL IL173253A patent/IL173253A0/en unknown
- 2006-02-23 NO NO20060898A patent/NO20060898L/no not_active Application Discontinuation
-
2010
- 2010-04-26 HR HR20100240T patent/HRP20100240T1/hr unknown
- 2010-04-30 US US12/771,345 patent/US20100247561A1/en not_active Abandoned
- 2010-05-14 CY CY20101100419T patent/CY1110028T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007502101A (ja) | 2007-02-08 |
| CY1110028T1 (el) | 2015-01-14 |
| IS8213A (is) | 2005-12-30 |
| IL173253A0 (en) | 2006-06-11 |
| PL1651166T3 (pl) | 2010-08-31 |
| AU2004258979B2 (en) | 2007-12-06 |
| NZ570750A (en) | 2009-12-24 |
| RU2337108C2 (ru) | 2008-10-27 |
| MXPA06000854A (es) | 2006-03-30 |
| CA2532370A1 (en) | 2005-02-03 |
| WO2005009379A3 (en) | 2006-11-30 |
| RU2006105498A (ru) | 2006-09-10 |
| EP1651166B1 (en) | 2010-02-17 |
| KR20060065643A (ko) | 2006-06-14 |
| DE602004025579D1 (de) | 2010-04-01 |
| ATE457737T1 (de) | 2010-03-15 |
| NZ544542A (en) | 2009-01-31 |
| EP1651166A2 (en) | 2006-05-03 |
| EP1651166A4 (en) | 2008-03-05 |
| EP1651166B8 (en) | 2010-05-19 |
| NO20060898L (no) | 2006-04-24 |
| AU2004258979A1 (en) | 2005-02-03 |
| US20060177462A1 (en) | 2006-08-10 |
| US20100247561A1 (en) | 2010-09-30 |
| WO2005009379A2 (en) | 2005-02-03 |
| PT1651166E (pt) | 2010-04-23 |
| SI1651166T1 (sl) | 2010-06-30 |
| ES2342778T3 (es) | 2010-07-14 |
| BRPI0412799A (pt) | 2006-09-26 |
| DK1651166T3 (da) | 2010-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100240T1 (hr) | Polipeptidi za indukciju zaštitnog imunitetnog odgovora protiv staphylococcus aureus | |
| JP2007502101A5 (hr) | ||
| Baratova et al. | The organization of potato virus X coat proteins in virus particles studied by tritium planigraphy and model building | |
| JP2009540801A5 (hr) | ||
| EP1578922A2 (en) | Replikin peptides in rapid replication of glioma cells and in influenza epidemics | |
| IL172396A (en) | CORONA virus peptides, a vaccine against the CORONA virus that contains them, methods for identifying and using them | |
| AU2002309514A1 (en) | Replikin peptides and uses thereof | |
| PH12021550030A1 (en) | Nucleotide sequences encoding peptide antigens of sars-cov-2 virus and use thereof | |
| RU2014126587A (ru) | Химерная частица hpv | |
| JP7146926B2 (ja) | Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン | |
| CA3233697A1 (en) | Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein | |
| HRP20100340T1 (hr) | Polipeptidi koji imaju antimikrobno djelovanje i polinukleotidi koji ih kodiraju | |
| TW200716166A (en) | Lawsonia intracellularis immunological proteins | |
| KR100906102B1 (ko) | 레플리킨 펩타이드 및 그의 이용 | |
| EP1419175A2 (en) | Replikin peptides and uses thereof | |
| ES2366176T3 (es) | Citocinas aviares novedosas y secuencias genéticas que codifican para las mismas. | |
| IE871169L (en) | Vaccine against varicella-zoster virus | |
| CN102612559B (zh) | 源自流感m2的修饰的肽疫苗 | |
| CN106480070A (zh) | 一种用于展示目的多肽的多肽载体及其用途 | |
| JPS59501866A (ja) | 腸内ウイルスに対するワクチン接種に有用なポリペプチド | |
| KR101635673B1 (ko) | Ａ형 간염 바이러스 백신 소재 단백질 ｖｐ1-3ｎ 및 백신 조성물 | |
| CN107344969B (zh) | 一种纳米流感疫苗及构建方法和应用 | |
| KR102647829B1 (ko) | 삼량체를 형성하는 코로나-19 바이러스 (COVID-19, Coronavirus Disease 2019)의 재조합 스파이크 단백질 및 식물에서의 상기 재조합 스파이크 단백질의 대량 생산 방법과 이를 기반으로하는 백신조성물 제조 방법 | |
| CN116262781A (zh) | 抗菌肽defensin衍生物及其原核表达方法与应用 | |
| CN113248576A (zh) | 一种针对冠状病毒的核酸疫苗及其制备方法 |